High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Blood

Volumn 99, Issue 9, 2002, Pages 3472-3475

  Branford, Susan ^a,b,c,d,e,f   Rudzki, Zbigniew ^a,b,c,d,e,f   Walsh, Sonya ^a,b,c,d,e,f   Grigg, Andrew ^a,b,c,d,e,f   Arthur, Chris ^a,b,c,d,e,f   Taylor, Kerry ^a,b,c,d,e,f   Herrmann, Richard ^a,b,c,d,e,f   Lynch, Kevin P ^a,b,c,d,e,f   Hughes, Timothy P ^a,b,c,d,e,f  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d MATER ADULT HOSPITAL   (Australia)

^e ROYAL PERTH HOSPITAL   (Australia)

^f Novartis Pharmaceuticals Australia Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; GLIVIC; IMATINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BINDING SITE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DRUG PROTEIN BINDING; FEMALE; GENETIC SCREENING; HUMAN; MALE; MOLECULAR INTERACTION; NUCLEOTIDE SEQUENCE; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 0036566540     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.9.3472     Document Type: Article

References (19)

1. Chronic myeloid leukemia
2. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
3. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
4. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
5. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
6. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
7. Mechanism of resistance to the ABL tyrosine kinase inhibitor sTI571 in BCR/ABL-transformed hematopoietic cell lines
8. Mechanisms of resistance imatinib (STI571) preclinical models and in leukemia patients
9. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
10. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
11. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics
12. A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1 b in a patient with Philadelphia-positive chronic myeloid leukaemia
13. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
14. An activating mutation in the ATP binding site of the ABL kinase domain
15. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain autophosphorylation at two distinct regulatory tyrosines
16. A point mutation in the ABL catalytic domain induces resistance to the tyrosine kinase inhibitor STI571
17. Roots of clinical resistance to STI-571 cancer therapy
18. Roots of clinical resistance to STI-571 cancer therapy
19. Roots of clinical resistance to STI-571 cancer therapy